AMRN — Amarin Corporation plc

Amarin Corporation plc Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Net Revenue: $49.2 million, down from $62.3 million in Q4 2024.
• U.S. Sales: Declined by 7% due to a decrease in net selling price.
• Product Revenue from Europe: $2.3 million, including $0.9 million from supply shipments to Recordati.
• Rest of World Revenue: $3.1 million, down from $11.9 million in Q4 2024, impacted by prior year stocking orders.
• Operating Expenses: Reduced by 31% to $30 million, with significant declines in cost of goods sold (down 63%) and SG&A (down 46%).
• Operating Loss: Narrowed to $2.3 million from $16 million in Q4 2024.
• Cash Position: Ended 2025 with $303 million in cash and investments, no debt, and working capital of $455 million.
• Positive Cash Flow from Operations: $7.0 million for the year.

2. Strategic Updates and Business Highlights:

• Established a long-term partnership with Recordati to commercialize Vazkepa in Europe, aiming to leverage their expertise in cardiovascular disease.
• Achieved approximately half of the estimated $70 million in operating expense savings from a global restructuring plan, with full savings expected by mid-2026.
• Maintained market leadership in the U.S. for Vascepa despite the introduction of generics.
• Continued to support scientific research, with over 500 peer-reviewed publications backing Vascepa's efficacy.

3. Forward Guidance and Outlook:

• Anticipates 2026 as a pivotal year, focusing on defending the U.S. franchise and expanding international presence through partnerships.
• Expects to generate positive cash flow for the full year in 2026, supported by a lower expense profile and ongoing revenue generation.
• Management is exploring strategic opportunities to enhance shareholder value.

4. Bad News, Challenges, or Points of Concern:

• Declining revenue in both U.S. and international markets, particularly in Rest of World sales due to prior year stocking orders.
• Ongoing pricing pressure in the U.S. market, influenced by competition from generics.
• Uncertainty surrounding the maintenance of exclusivity with payers, as evidenced by past fluctuations in PBM relationships.

5. Notable Q&A Insights:

• Management acknowledged consistent volume and pricing dynamics in Q4, with expectations of initial volume declines in Q1 2026.
• Confidence expressed in maintaining exclusivity with existing formulary agreements, though acknowledging the dynamic nature of the market.
• The potential impact of new premium-priced therapies entering the market and the need for established therapies like Vascepa to remain relevant amidst evolving treatment landscapes.

Overall, while Amarin has made significant strides in restructuring and establishing partnerships, it faces challenges in revenue generation and market competition that will require careful navigation in the upcoming year.